Selected research
Market Structure
Global Tuberculosis Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Tuberculosis Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Tuberculosis Vaccines include Bavarian Nordic, China National Biotec Group, GreenSignal Bio Pharma, IDT Biologics, Japan BCG Lab, Serum Institute of India, Taj Pharmaceuticals, GlaxoSmithKline and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Tuberculosis Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Tuberculosis Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Tuberculosis Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
Tuberculosis Vaccines Segment by Company
Bavarian Nordic
China National Biotec Group
GreenSignal Bio Pharma
IDT Biologics
Japan BCG Lab
Serum Institute of India
Taj Pharmaceuticals
GlaxoSmithKline
Merck
Sanofi
Tuberculosis Vaccines Segment by Type
Immunotherapeutic Vaccines
Booster Vaccines
Others
Tuberculosis Vaccines Segment by Application
Hospitals
Clinics
Others
Tuberculosis Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Tuberculosis Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tuberculosis Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Tuberculosis Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapeutic Vaccines
- Booster Vaccines
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Bavarian Nordic
- China National Biotec Group
- GreenSignal Bio Pharma
- IDT Biologics
- Japan BCG Lab
- Serum Institute of India
- Taj Pharmaceuticals
- GlaxoSmithKline
- Merck
- Sanofi
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Tuberculosis Vaccines Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Tuberculosis Vaccines Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Tuberculosis Vaccines Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Tuberculosis Vaccines Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Tuberculosis Vaccines Market Dynamics
- 2.1 Tuberculosis Vaccines Industry Trends
- 2.2 Tuberculosis Vaccines Industry Drivers
- 2.3 Tuberculosis Vaccines Industry Opportunities and Challenges
- 2.4 Tuberculosis Vaccines Industry Restraints
3 Tuberculosis Vaccines Market by Manufacturers
- 3.1 Global Tuberculosis Vaccines Revenue by Manufacturers (2021-2026)
- 3.2 Global Tuberculosis Vaccines Sales by Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Vaccines Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Tuberculosis Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Tuberculosis Vaccines Manufacturers, Product Type & Application
- 3.7 Global Tuberculosis Vaccines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Tuberculosis Vaccines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Tuberculosis Vaccines Players Market Share by Revenue in 2025
- 3.8.3 2025 Tuberculosis Vaccines Tier 1, Tier 2, and Tier 3
4 Tuberculosis Vaccines Market by Type
- 4.1 Tuberculosis Vaccines Type Introduction
- 4.1.1 Immunotherapeutic Vaccines
- 4.1.2 Booster Vaccines
- 4.1.3 Others
- 4.2 Global Tuberculosis Vaccines Sales by Type
- 4.2.1 Global Tuberculosis Vaccines Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Tuberculosis Vaccines Sales by Type (2021-2032)
- 4.2.3 Global Tuberculosis Vaccines Sales Market Share by Type (2021-2032)
- 4.3 Global Tuberculosis Vaccines Revenue by Type
- 4.3.1 Global Tuberculosis Vaccines Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Tuberculosis Vaccines Revenue by Type (2021-2032)
- 4.3.3 Global Tuberculosis Vaccines Revenue Market Share by Type (2021-2032)
5 Tuberculosis Vaccines Market by Application
- 5.1 Tuberculosis Vaccines Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.1.3 Others
- 5.2 Global Tuberculosis Vaccines Sales by Application
- 5.2.1 Global Tuberculosis Vaccines Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Tuberculosis Vaccines Sales by Application (2021-2032)
- 5.2.3 Global Tuberculosis Vaccines Sales Market Share by Application (2021-2032)
- 5.3 Global Tuberculosis Vaccines Revenue by Application
- 5.3.1 Global Tuberculosis Vaccines Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Tuberculosis Vaccines Revenue by Application (2021-2032)
- 5.3.3 Global Tuberculosis Vaccines Revenue Market Share by Application (2021-2032)
6 Global Tuberculosis Vaccines Sales by Region
- 6.1 Global Tuberculosis Vaccines Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Tuberculosis Vaccines Sales by Region (2021-2032)
- 6.2.1 Global Tuberculosis Vaccines Sales by Region (2021-2026)
- 6.2.2 Global Tuberculosis Vaccines Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Tuberculosis Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Tuberculosis Vaccines Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Tuberculosis Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Tuberculosis Vaccines Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Tuberculosis Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Tuberculosis Vaccines Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Tuberculosis Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Tuberculosis Vaccines Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Tuberculosis Vaccines Revenue by Region
- 7.1 Global Tuberculosis Vaccines Revenue by Region
- 7.1.1 Global Tuberculosis Vaccines Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Tuberculosis Vaccines Revenue by Region (2021-2026)
- 7.1.3 Global Tuberculosis Vaccines Revenue by Region (2027-2032)
- 7.1.4 Global Tuberculosis Vaccines Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Tuberculosis Vaccines Revenue (2021-2032)
- 7.2.2 North America Tuberculosis Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Tuberculosis Vaccines Revenue (2021-2032)
- 7.3.2 Europe Tuberculosis Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Tuberculosis Vaccines Revenue (2021-2032)
- 7.4.2 Asia-Pacific Tuberculosis Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Tuberculosis Vaccines Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Tuberculosis Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bavarian Nordic
- 8.1.1 Bavarian Nordic Company Information
- 8.1.2 Bavarian Nordic Business Overview
- 8.1.3 Bavarian Nordic Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bavarian Nordic Tuberculosis Vaccines Product Portfolio
- 8.1.5 Bavarian Nordic Recent Developments
- 8.2 China National Biotec Group
- 8.2.1 China National Biotec Group Company Information
- 8.2.2 China National Biotec Group Business Overview
- 8.2.3 China National Biotec Group Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 China National Biotec Group Tuberculosis Vaccines Product Portfolio
- 8.2.5 China National Biotec Group Recent Developments
- 8.3 GreenSignal Bio Pharma
- 8.3.1 GreenSignal Bio Pharma Company Information
- 8.3.2 GreenSignal Bio Pharma Business Overview
- 8.3.3 GreenSignal Bio Pharma Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 GreenSignal Bio Pharma Tuberculosis Vaccines Product Portfolio
- 8.3.5 GreenSignal Bio Pharma Recent Developments
- 8.4 IDT Biologics
- 8.4.1 IDT Biologics Company Information
- 8.4.2 IDT Biologics Business Overview
- 8.4.3 IDT Biologics Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 IDT Biologics Tuberculosis Vaccines Product Portfolio
- 8.4.5 IDT Biologics Recent Developments
- 8.5 Japan BCG Lab
- 8.5.1 Japan BCG Lab Company Information
- 8.5.2 Japan BCG Lab Business Overview
- 8.5.3 Japan BCG Lab Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Japan BCG Lab Tuberculosis Vaccines Product Portfolio
- 8.5.5 Japan BCG Lab Recent Developments
- 8.6 Serum Institute of India
- 8.6.1 Serum Institute of India Company Information
- 8.6.2 Serum Institute of India Business Overview
- 8.6.3 Serum Institute of India Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Serum Institute of India Tuberculosis Vaccines Product Portfolio
- 8.6.5 Serum Institute of India Recent Developments
- 8.7 Taj Pharmaceuticals
- 8.7.1 Taj Pharmaceuticals Company Information
- 8.7.2 Taj Pharmaceuticals Business Overview
- 8.7.3 Taj Pharmaceuticals Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Taj Pharmaceuticals Tuberculosis Vaccines Product Portfolio
- 8.7.5 Taj Pharmaceuticals Recent Developments
- 8.8 GlaxoSmithKline
- 8.8.1 GlaxoSmithKline Company Information
- 8.8.2 GlaxoSmithKline Business Overview
- 8.8.3 GlaxoSmithKline Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 GlaxoSmithKline Tuberculosis Vaccines Product Portfolio
- 8.8.5 GlaxoSmithKline Recent Developments
- 8.9 Merck
- 8.9.1 Merck Company Information
- 8.9.2 Merck Business Overview
- 8.9.3 Merck Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Merck Tuberculosis Vaccines Product Portfolio
- 8.9.5 Merck Recent Developments
- 8.10 Sanofi
- 8.10.1 Sanofi Company Information
- 8.10.2 Sanofi Business Overview
- 8.10.3 Sanofi Tuberculosis Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Sanofi Tuberculosis Vaccines Product Portfolio
- 8.10.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Tuberculosis Vaccines Value Chain Analysis
- 9.1.1 Tuberculosis Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Tuberculosis Vaccines Production Mode & Process
- 9.2 Tuberculosis Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Tuberculosis Vaccines Distributors
- 9.2.3 Tuberculosis Vaccines Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst